Overview

Dose Response of Dance 501 in Subjects With Type 2 Diabetes Mellitus

Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This will be a randomized, open-label, active-controlled, 6-period crossover study. Target population will be subjects with Type 2 Diabetes Mellitus (T2DM)
Phase:
Phase 2
Details
Lead Sponsor:
Dance Biopharm Inc.
Collaborator:
Profil Institut für Stoffwechselforschung GmbH
Treatments:
Insulin
Insulin Lispro
Insulin, Globin Zinc